MAIA Biotechnology, Inc. (MAIA)

NYSE Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$10.9M
Cash & Equivalents
$5.3M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$88M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT06908304 A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC PHASE3 Recruiting 300
NCT05208944 THIO Sequenced With Cemiplimab in Advanced NSCLC PHASE2 Active Not Recruiting 227

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for MAIA.

SEC EDGAR Filings

All SEC filings for MAIA Biotechnology, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.